HRP20170964T1 - Tiadiazolidindioni kao inhibitori gsk-3 - Google Patents

Tiadiazolidindioni kao inhibitori gsk-3 Download PDF

Info

Publication number
HRP20170964T1
HRP20170964T1 HRP20170964TT HRP20170964T HRP20170964T1 HR P20170964 T1 HRP20170964 T1 HR P20170964T1 HR P20170964T T HRP20170964T T HR P20170964TT HR P20170964 T HRP20170964 T HR P20170964T HR P20170964 T1 HRP20170964 T1 HR P20170964T1
Authority
HR
Croatia
Prior art keywords
compound
formula
solvate
salt
compound according
Prior art date
Application number
HRP20170964TT
Other languages
English (en)
Croatian (hr)
Inventor
Miguel Medina Padilla
Juan Manuel DOMÍNGUEZ CORREA
Javier DE CRISTOBAL BLANCO
Ana Fuertes Huerta
Jorge Sánchez-Quesada
Javier LÓPEZ OGALLA
Susana Herrero Santos
María Ángeles PÉREZ DE LA CRUZ MORENO
Olga MARTÍNEZ MONTERO
Beatriz RODRÍGUEZ SALGUERO
Francisco Palomo Nicolau
Original Assignee
Asd Therapeutics Partners Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asd Therapeutics Partners Llc filed Critical Asd Therapeutics Partners Llc
Publication of HRP20170964T1 publication Critical patent/HRP20170964T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20170964TT 2012-02-24 2013-02-22 Tiadiazolidindioni kao inhibitori gsk-3 HRP20170964T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382066 2012-02-24
PCT/EP2013/053554 WO2013124413A1 (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors
EP13705492.0A EP2838888B1 (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
HRP20170964T1 true HRP20170964T1 (hr) 2017-10-06

Family

ID=47747639

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170964TT HRP20170964T1 (hr) 2012-02-24 2013-02-22 Tiadiazolidindioni kao inhibitori gsk-3

Country Status (18)

Country Link
US (2) US9371299B2 (enExample)
EP (1) EP2838888B1 (enExample)
JP (2) JP6073377B2 (enExample)
AU (2) AU2013224041B2 (enExample)
CA (1) CA2865351C (enExample)
CY (1) CY1119231T1 (enExample)
DK (1) DK2838888T3 (enExample)
ES (1) ES2632428T3 (enExample)
HR (1) HRP20170964T1 (enExample)
HU (1) HUE035089T2 (enExample)
IN (1) IN2014DN07885A (enExample)
LT (1) LT2838888T (enExample)
NZ (1) NZ630615A (enExample)
PL (1) PL2838888T3 (enExample)
PT (1) PT2838888T (enExample)
SI (1) SI2838888T1 (enExample)
WO (1) WO2013124413A1 (enExample)
ZA (1) ZA201406225B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2838888B1 (en) 2012-02-24 2017-04-12 ASD Therapeutics Partners LLC Thiadiazolidinediones as gsk-3 inhibitors
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
MX388409B (es) * 2014-06-12 2025-03-19 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
CN113168150B (zh) * 2018-10-16 2024-05-10 意大利技术联盟有限责任公司 具有被处理幅材的评估系统的卷绕机和方法
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2022170437A1 (en) * 2021-02-11 2022-08-18 Venca Research, Inc. Compositions and methods for treating arrhythmogenic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
DE60129222T2 (de) * 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
EP2838888B1 (en) 2012-02-24 2017-04-12 ASD Therapeutics Partners LLC Thiadiazolidinediones as gsk-3 inhibitors

Also Published As

Publication number Publication date
ES2632428T3 (es) 2017-09-13
PT2838888T (pt) 2017-07-18
EP2838888B1 (en) 2017-04-12
CY1119231T1 (el) 2018-02-14
HUE035089T2 (hu) 2018-05-02
AU2017248556A1 (en) 2017-11-09
HK1207366A1 (en) 2016-01-29
CA2865351C (en) 2019-08-20
EP2838888A1 (en) 2015-02-25
JP2017081974A (ja) 2017-05-18
CA2865351A1 (en) 2013-08-29
US20150038538A1 (en) 2015-02-05
US9371299B2 (en) 2016-06-21
US9469618B2 (en) 2016-10-18
US20160257660A1 (en) 2016-09-08
IN2014DN07885A (enExample) 2015-04-24
JP6518270B2 (ja) 2019-05-22
AU2013224041B2 (en) 2017-08-24
AU2017248556B2 (en) 2018-08-09
ZA201406225B (en) 2016-05-25
JP6073377B2 (ja) 2017-02-01
NZ630615A (en) 2015-09-25
SI2838888T1 (sl) 2017-09-29
DK2838888T3 (en) 2017-07-17
WO2013124413A1 (en) 2013-08-29
PL2838888T3 (pl) 2017-12-29
AU2013224041A1 (en) 2014-09-25
JP2015508092A (ja) 2015-03-16
LT2838888T (lt) 2017-08-10

Similar Documents

Publication Publication Date Title
JP2015508092A5 (enExample)
RU2016118768A (ru) Композиции, пригодные для лечения расстройств, связанных с kit
EA201070871A1 (ru) Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии
JP2017509689A5 (enExample)
JP2009511508A5 (enExample)
RU2015135005A (ru) Ингибиторы ras и их применение
AR058379A1 (es) Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.
JP2022070895A (ja) ニューロキニン-1受容体アンタゴニストとしての化合物およびその使用
FI4159217T3 (fi) Mek-estäjän ja b-raf-estäjän käsittävä yhdistelmä
ATE531711T1 (de) Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate
BR112012020557A2 (pt) formas cristalinas de sódio 4- {[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido [5,4-d] [2] benzazepin-2-il]-amino}-2 metoxibenzoato de sódio.
HRP20120696T1 (hr) Spiro-prstenasti spoj i njegova medicinska upotreba
WO2009112678A3 (fr) Derives de carboxam i d es azabicycliques, leur preparation et leur application en therapeutique.
JP2008508360A5 (enExample)
EP2077846A4 (en) BENZOXAZEPINE COMPOUNDS, PREPARATION THEREOF AND USE THEREOF
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
AR063454A1 (es) Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas.
IN2014DN01993A (enExample)
JP2013514980A5 (enExample)
CO6210701A2 (es) Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico
RU2010116374A (ru) Бензил-циклоалкильные модуляторы рецепторов сфингозин-1-фосфата
FI3820872T3 (fi) Pyrrolo[1,2-b]pyridatsiinijohdannaiset
JP2015502371A5 (enExample)
JP2017521364A5 (enExample)
DK1961734T3 (da) Aminforbindelse og anvendelse deraf til medicinske formål